The life sciences sector saw an increase in the percentage of companies falling under one or both proxy firms’ Board Responsiveness Policies as well as declining average support for pay votes. These results signal that investors are increasingly unwilling to provide corporate issuers the benefit of the doubt in a continued trend of escalating CEO pay levels and more volatile stock prices.